Figure 7.

(A) Percentages of covalent interaction in the SE-HPLC-isolated ICG-sOSu-panitumumab conjugates (1, 2, 3). Ethyl acetate was used to remove noncovalently bound ICG-sOSu. (B) Competition radioimmunoassay, with ¹²⁵I-panitumumab, of SE-HPLC-isolated ICG-sOSu-panitumumab before (2) and after (5) extraction by ethyl acetate. Unmodified panitumumab monoclonal antibody served as a positive control. In addition, unmodified panitumumab after ethyl acetate extraction (panitumumab-e) was also examined. HuM195 served as a negative control.